ClinicalTrials.gg
RecruitingNCT02937649BOUSTUpdated Apr 6, 2025

Bougie Sleeve Trial

An interventional study of Laparoscopic sleeve gastrectomy using 48-Fr bougie and Laparoscopic sleeve gastrectomy using standard care bougie in Morbid Obesity, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 12 sites in France. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-04-06.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Oct 2020; still recruiting 6 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,658
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Obesity, Morbid by Assistance Publique - Hôpitaux de Paris — 3 open to participants now, 5 under way, none of them phase 3. Obesity, Morbid · Assistance Publique - Hôpitaux de Paris.

Started
2020
the only one that year
No phase
7 of 13
3 open now
Registered
6th of 13
by date

Among the 13 studies in Obesity, Morbid by Assistance Publique - Hôpitaux de Paris, this one is the only one that started in 2020, is one of 7 with no phase, and was the 6th registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

3 of the 13 studies in Obesity, Morbid by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Obesity, Morbid by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Staple-line leak is the most frequent and incapacitating complication after laparoscopic sleeve gastrectomy (LSG). The aim of this prospective randomized trial is to compare the staple-line leak rate after LSG according to the use of a standard bougie calibre (34, 36 or 38 Fr) or 48-Fr, assuming that a higher diameter is correlated with a lower risk of leak, without lowering long-term weight loss.

Read the detailed description

Laparoscopic sleeve gastrectomy (LSG) has become an increasing bariatric procedure. The most common complication is gastric leak from the staple line, observed in approximately 3% of cases, and can result in long and incapacitating treatment. The diameter of the bougie used to calibrate the remnant stomach could impact the rate of gastric leak, a higher diameter being correlated with a lower risk of leak, without lowering long-term weight loss.

The aim of this prospective randomized trial is to compare the outcomes of LSG according to the use of a standard care bougie calibre or 48-Fr on postoperative gastric leak and mid-term weight loss.

03

Conditions studied

  • Morbid Obesity

Keywords

  • Obesity
  • Bariatric surgery
  • Sleeve gastrectomy
  • Staple-line Leak
  • Bougie
  • Calibration
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients between 18 and 70 years
  • Sleeve gastrectomy as a primary bariatric procedure
  • (BMI) > 40 kg/m² or > 35 kg/m² associated with at least one comorbidity susceptible to improve after surgery (including arterial hypertension, obstructive sleep apnea syndrome and other severe respiratory disorders, severe metabolic disorders, particularly type 2 diabetes, incapacitating osteo-articular disorders, non alcoholic steatohepatitis)
  • Decision for intervention after multidisciplinary discussion
  • Written

Exclusion criteria

Exclusion Criteria:

  • Previous upper abdominal surgery (cholecystectomy excepted)
  • ASA () score > 3
  • Ongoing pregnancy or breast feeding
  • Esophagus pathology or disorder (esophageal varices, esophageal diverticula, esophageal tumors, esophageal strictures)
  • Coagulation disorder
  • Patient not covered by social security service and patient on AME
  • Patient under legal guardianship and trusteeship
  • Patient with known silicon allergy (calibration bougie contains medical silicon)
  • More generally, all other to the use of esophageal bougie MID-TUBE that have been the subject of a scientific paper or have been identified by the practitioner or practitioners
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
1,658 participants (estimated)

Study arms

  • Experimental
    Laparoscopic sleeve gastrectomy using 48-Fr bougie

    Patients will undergo laparoscopic sleeve gastrectomy with a 48-Fr (16 mm) bougie

    Procedure: Laparoscopic sleeve gastrectomy using 48-Fr bougie

  • Active comparator
    Laparoscopic sleeve gastrectomy using standard care bougie

    Patients will undergo laparoscopic sleeve gastrectomy with a standard care bougie (34, 36 or 38-Fr)

    Procedure: Laparoscopic sleeve gastrectomy using standard care bougie

Interventions

  • ProcedureLaparoscopic sleeve gastrectomy using 48-Fr bougie

    After gastric mobilization, the 48-Fr bougie is inserted through the mouth by the anesthesiologist and positioned in the stomach. Patient is blind to the type of bougie used. Gastrectomy is performed alongside the calibration bougie.

  • ProcedureLaparoscopic sleeve gastrectomy using standard care bougie

    After gastric mobilization, the standard care bougie is inserted through the mouth by the anesthesiologist and positioned in the stomach. Patient is blind to the type of bougie used. Gastrectomy is performed alongside the calibration bougie.

06

What researchers measure

Primary outcomes

  1. Postoperative gastric leak rate

    Postoperative gastric leak rate during the first month following the procedure will be proven either on: * Morphologic examination (with contrast ingestion) * Blue dye test during surgical reintervention or postoperative course * Contrast opacification during endoscopy

    Time frame: 30 days following the procedure

Secondary outcomes

  1. Postoperative morbidity rate

    Postoperative morbidity rate will be calculated regarding any complication occurring 90 days following the procedure.

    Time frame: 90 days following the procedure

  2. Short-term weight loss

    Short-term weight loss will be assessed by calculation of excess weight loss at 3 and 6 months after the procedure.

    Time frame: At 3 and 6 months after the procedure

  3. Mid-term weight loss

    Mid-term weight loss will be assessed by calculation of excess weight loss at 1 and 2 years after the procedure.

    Time frame: At 1 and 2 years after the procedure

  4. Quality of life related to health

    Quality of life related to health will be assessed at 3 months, 6 months, 1 year and 2 years after the procedure with the validated GIQLI scale (Gastro Intestinal Quality of Life Index)

    Time frame: At 3 months, 6 months, 1 year and 2 years after the procedure

07

Study locations

6 of 12 sites recruiting
  • Hôpital Ambroise Paré
    Boulogne-Billancourt, 92104, France
    Suspended

    Not enrolling at this site.

  • Hôpital Côte de Nacre CHU de Caen
    Caen, 14033, France
    Withdrawn

    Not enrolling at this site.

  • CHU Antoine Béclère
    Clamart, 92140, France
    Recruiting
  • Centre hospitalier Intercommunal de Créteil
    Créteil, 94010, France
    Withdrawn

    Not enrolling at this site.

  • Hôpital MICHALLON, CHU de Grenoble
    La Tronche, 38700, France
    Withdrawn

    Not enrolling at this site.

  • Hôpital Dupuytren - Limoges
    Limoges, 87042, France
    Withdrawn

    Not enrolling at this site.

  • Clinique de l'Yvette
    Longjumeau, 91120, France
    Recruiting
    • Aziz KARAA, Dr · Contact
  • Service de chirurgie générale et digestive, œsogastrique et bariatrique - Hôpital Bichat
    Paris, 75018, France
    Recruiting
    • Tigran POGHOSYAN, Dr · Contact
  • CHI - Centre Hospitalier Poissy/Saint-Germain-en-Laye
    Poissy, 78300, France
    Recruiting
    • Antonio D'ALESSANDRO, Dr · Contact
  • CH Saint-Denis
    Saint-Denis, 93200, France
    Recruiting
    • Jean-Marc CATHELINE · Contact
  • Clinique Mutualiste Chirurgicale
    Saint-Étienne, 42100, France
    Withdrawn

    Not enrolling at this site.

  • Hôpitaux de Brabois
    Vandœuvre-lès-Nancy, 54500, France
    Recruiting
    • Laurent BRUNAUD, Dr · Contact
08

References and documents

Publications

  • Gaillard M, Lainas P, Agostini H, Dagher I, Tranchart H. Impact of the calibration bougie diametre during laparoscopic sleeve gastrectomy on the rate of postoperative staple-line leak (BOUST): study protocol for a multicentre randomized prospective trial. Trials. 2021 Nov 15;22(1):806. doi: 10.1186/s13063-021-05734-3. PubMed 34781991 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2020 (actual). Primary completion is estimated for Jun 2025, 56 months after the start.

Of 273 non-industry interventional studies with no phase under Obesity, Morbid, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's planned 56 months is above that.

Counting every sponsor, half of 285 studies reached it within 25 months; a quarter within 11 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2016
First posted
Oct 18, 2016
StartActual
Oct 8, 2020
Primary completionEst.
Jun 8, 2025
CompletionEst.
Sep 8, 2027
Last update
Apr 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02937649
Responsible party
Sponsor
First posted
Oct 18, 2016
Start date
Oct 8, 2020
Primary completion
Jun 8, 2025 (estimated)
Completion
Sep 8, 2027 (estimated)
Last update
Apr 6, 2025

Study contacts

Hadrien TRANCHART, Dr
Contact
hadrien.tranchart@aphp.fr
(+33)145374037
Ibrahim DAGHER, Pr
Contact
ibrahim.dagher@aphp.fr
(+33)145374143
Hadrien TRANCHART, Dr
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion